254 related articles for article (PubMed ID: 12231077)
1. Rationale for and role of thiazolidinediones in type 2 diabetes mellitus.
Lebovitz HE
Am J Cardiol; 2002 Sep; 90(5A):34G-41G. PubMed ID: 12231077
[TBL] [Abstract][Full Text] [Related]
2. Thiazolidinediones in the treatment of managed care patients with type 2 diabetes.
Pathak R; Afaq A; Blonde L
Am J Manag Care; 2002 Oct; 8(16 Suppl):S483-94. PubMed ID: 12408411
[TBL] [Abstract][Full Text] [Related]
3. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
Krentz AJ; Bailey CJ
Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
[TBL] [Abstract][Full Text] [Related]
4. Beneficial effects resulting from thiazolidinediones for treatment of type 2 diabetes mellitus.
Bell DS
Postgrad Med; 2003 May; Spec No():35-44. PubMed ID: 12785130
[TBL] [Abstract][Full Text] [Related]
5. New developments in type 2 diabetes mellitus: combination therapy with a thiazolidinedione.
Braunstein S
Clin Ther; 2003 Jul; 25(7):1895-917. PubMed ID: 12946541
[TBL] [Abstract][Full Text] [Related]
6. New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers.
Mudaliar S; Henry RR
Annu Rev Med; 2001; 52():239-57. PubMed ID: 11160777
[TBL] [Abstract][Full Text] [Related]
7. Effects of thiazolidinediones for early treatment of type 2 diabetes mellitus.
Kudzma DJ
Am J Manag Care; 2002 Oct; 8(16 Suppl):S472-82. PubMed ID: 12408410
[TBL] [Abstract][Full Text] [Related]
8. Progress with thiazolidinediones in the management of type 2 diabetes mellitus.
Meriden T
Clin Ther; 2004 Feb; 26(2):177-90. PubMed ID: 15038941
[TBL] [Abstract][Full Text] [Related]
9. Insulin sensitizers.
Zangeneh F; Kudva YC; Basu A
Mayo Clin Proc; 2003 Apr; 78(4):471-9. PubMed ID: 12683699
[TBL] [Abstract][Full Text] [Related]
10. Addressing the insulin resistance syndrome: a role for the thiazolidinediones.
Zimmet P
Trends Cardiovasc Med; 2002 Nov; 12(8):354-62. PubMed ID: 12536122
[TBL] [Abstract][Full Text] [Related]
11. Where thiazolidinediones will fit.
Reasner CA
Diabetes Metab Res Rev; 2002; 18 Suppl 2():S30-5. PubMed ID: 11921436
[TBL] [Abstract][Full Text] [Related]
12. A review of metabolic and cardiovascular effects of oral antidiabetic agents: beyond glucose-level lowering.
Ginsberg H; Plutzky J; Sobel BE
J Cardiovasc Risk; 1999 Oct; 6(5):337-46. PubMed ID: 10534139
[TBL] [Abstract][Full Text] [Related]
13. Durability of glycemic control: a feature of the thiazolidinediones.
Serdy S; Abrahamson MJ
Diabetes Technol Ther; 2004 Apr; 6(2):179-89. PubMed ID: 15117584
[TBL] [Abstract][Full Text] [Related]
14. Type 2 diabetes, cardiovascular risk, and the link to insulin resistance.
Stolar MW; Chilton RJ
Clin Ther; 2003; 25 Suppl B():B4-31. PubMed ID: 14553864
[TBL] [Abstract][Full Text] [Related]
15. Management of co-existing diabetes mellitus and dyslipidemia: defining the role of thiazolidinediones.
Florkowski CM
Am J Cardiovasc Drugs; 2002; 2(1):15-21. PubMed ID: 14727995
[TBL] [Abstract][Full Text] [Related]
16. Constructing an algorithm for managing type 2 diabetes. Focus on role of the thiazolidinediones.
Wyne KL; Drexler AJ; Miller JL; Bell DS; Braunstein S; Nuckolls JG
Postgrad Med; 2003 May; Spec No():63-72. PubMed ID: 12785133
[TBL] [Abstract][Full Text] [Related]
17. The pathophysiologic basis of efficacy and clinical experience with the new oral antidiabetic agents.
Rosak C
J Diabetes Complications; 2002; 16(1):123-32. PubMed ID: 11872380
[TBL] [Abstract][Full Text] [Related]
18. New oral thiazolidinedione antidiabetic agents act as insulin sensitizers.
Hofmann CA; Colca JR
Diabetes Care; 1992 Aug; 15(8):1075-8. PubMed ID: 1505314
[No Abstract] [Full Text] [Related]
19. Pioglitazone and sulfonylureas: effectively treating type 2 diabetes.
Hanefeld M
Int J Clin Pract Suppl; 2007 Jun; 61(153):20-7. PubMed ID: 17594390
[TBL] [Abstract][Full Text] [Related]
20. Insulin sensitisation in the treatment of Type 2 diabetes.
Tadayyon M; Smith SA
Expert Opin Investig Drugs; 2003 Mar; 12(3):307-24. PubMed ID: 12605557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
